Publisher
Springer International Publishing
Reference63 articles.
1. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 2007;44:159–77.
2. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins,immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24:S21–40.
https://doi.org/10.1016/j.cmi.2018.02.002
.
3. So W, Pandya S, Quilitz R, et al. Infectious risks and complications in adult leukemic patients receiving blinatumomab. Mediterr J Hematol Infect Dis. 2018;10(1):e2018029.
https://doi.org/10.4084/MJHID.2018.029
.
4. National comprehensive cancer network. Prevention and treatment of cancer-related infections version I. 2018. Accessed online on Apr 2018.
https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf
. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.
5. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;(4):CD004386.